Cusabio Technology LLC

圣诞节

平安夜

HNRNPC Recombinant Monoclonal Antibody
CSB-RA010605A0HU

WORLD AIDS DAY
Targeting Understanding,Advancing Hope

CD24: A Key Element in the EXO-CD24 Technique for Combating COVID-19- CUSABIO EXO-CD24 is a therapeutic technique for Combating COVID-19. If EXO-CD24 proves to be safe and effective, CD24 will largely participate in the COVID-19 therapy. What is CD24 and how might it work in CO...

🦠 #CD24 is a glycosylphosphatidylinositol (GPI)-anchored protein primarily expressed on immune cells, epithelial cells, and tumor cells. It plays a key role in immune regulation, particularly in dampening excessive immune responses. Read more: bit.ly/3Dc2M1O

GPRC5D: Newly Efficient GPRC5D CAR-T or Bispecific Antibody Therapy to Fight Multiple Myeloma (MM) - Cusabio GPRC5D (G Protein-Coupled Receptor Class C Group 5 Member D) has emerged as a promising therapeutic target, garnering significant attention in the field of oncology and immunotherapy. Particularly in ...

Amgen’s multi-million dollar investment in GPRC5D-targeted CAR-T therapy highlights its potential to reshape MM treatment. As research advances, could GPRC5D be the future of immunotherapy? Read more: bit.ly/42l1Emy

SSTR2: A Prominent Target in SSTR Family, Offers a More Precise Therapy in Neuroendocrine Tumors (NET) - Cusabio Recently, Sanofi invested $20 million to gain priority negotiation rights for Zucara Therapeutics' novel SSTR2-targeting drug candidate ZT-01 for type 1 diabetes. ZT-01, an SSTR2 receptor antagonist, ...

Recently, Sanofi’s $20M investment in ZT-01 for type 1 diabetes and Novartis’s $745M deal for SSTR2 radiotherapeutics both point to one thing: SSTR2 is emerging as a key target in modern drug development.

👉 Read more: bit.ly/4a1Dlw2

Dr. Lola Zerbib and her team highlight alpelisib, a PI3Kα inhibitor, as a breakthrough for #PIK3CA/TEK-related #VenousMalformations, reducing lesions by 33.4% (PIK3CA) and 27.8% (TEK) in therapy-resistant patients.
Learn more: www.nature.com/articles/s41...

🎉 As we celebrate CUSABIO’s 17th Anniversary, we invite you to share your story with us!

📅 Submission Deadline: February 15, 2025
🎁 𝟏𝟎𝟎% 𝐖𝐢𝐧 𝐑𝐚𝐭𝐞: Every approved story wins a prize!

👉 Celebrate with us: bit.ly/3Dnp1BH

#CUSABIO17 #Anniversary #Research #ShareYourStory

DDR1; Tumor Therapy; TME DDR1 has been newly identified as a member of the receptor tyrosine kinases (RTKs) family. It is widely recognized that RTKs control cell proliferation and differentiation, which are involved in tumor...

DDR1 plays key roles in cell proliferation, migration & tumor invasion. Recent research highlights its role in forming a barrier that blocks T cells, helping tumors evade immunity. Inhibiting DDR1 could restore immune cell activity, offering exciting potential for cancer treatment. bit.ly/4iUp7Ry

𝐇𝐞𝐥𝐥𝐨, 𝐁𝐥𝐮𝐞𝐬𝐤𝐲! 🌟

We’re CUSABIO, trusted by researchers worldwide for 17+ years. Our high-quality proteins, antibodies, and ELISA kits support research in cancer, immunology, neuroscience, and more. 🧪

“𝒀𝒐𝒖𝒓 𝒈𝒐𝒐𝒅 𝒑𝒂𝒓𝒕𝒏𝒆𝒓 𝒊𝒏 𝒃𝒊𝒐𝒍𝒐𝒈𝒚 𝒓𝒆𝒔𝒆𝒂𝒓𝒄𝒉.”

Follow us for updates and collaboration opportunities!